

ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955

- Email: contact@alkem.com
   Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

25<sup>th</sup> November, 2022

The Corporate Relationship Department	National Stock Exchange of India Limited
BSE Limited	Exchange Plaza,
Phiroze Jeejeebhoy Towers,	Bandra Kurla Complex,
Dalal Street,	Bandra East,
Mumbai 400 001.	Mumbai 400 051.
Scrip Code: 539523	Scrip Symbol: ALKEM

Dear Sirs,

## Sub: Disclosure of related party transactions on a consolidated basis under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosures of related party transactions, on a consolidated basis, for the half year ended on 30<sup>th</sup> September, 2022 in the prescribed format. The same have been published on the website of the Company at <u>www.alkemlabs.com</u>.

Kindly take the same on record.

Yours Faithfully,

For Alkem Laboratories Limited

Manish Narang President – Legal, Company Secretary and Compliance Officer

## Rs.In million Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subeidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

													such transaction was undertaken.										
97 VJ.			Details of the	Type of related party transaction	Details of other related party transaction	d Value of the related party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting		er party as t of the	In case any financia or give loans, inter			Details of the	loans, inter⊣	corporate de	posits, advan	ces or investments	Note				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee		period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	/	
1 A	ken Laboratories Limited	AABCA9521E	Cachet Pharmaceuticals Private	AAACC9312J	Subsidiary	Purchase of goods or services		2500.00	Approved by the audit committee of the entity	418.52	147.48	227.06	5									1	
2 A	kem Laboratories Limited	AABCA9521E	Cachet Pharmaceuticals Private	AAACC9312J	Subsidiary	Sale of goods or services		50.00	Approved by the audit committee of the entity	0.00	0.00	0.00	0										
3 A	kem Laboratories Limited	AABCA9521E	Cachet Pharmaceuticals Private	AAACC9312J	Subsidiary	Any other transaction	Services received	200.00	Approved by the audit committee of the entity	26.09	147.48	227.06	ò		1							1	
4 A	kem Laboratories Limited	AABCA9521E	Cachet Pharmaceuticals Private	AAACC9312J	Subsidiary	Any other transaction	Royalty expenses	2.00	Approved by the audit	0.32	147.48	227.06	5									+	
5 A	kem Laboratories Limited	AABCA9521E	Limited Cachet Pharmaceuticals Private	AAACC9312J	Subsidiary	Any other transaction	Rent Income	50.00	committee of the entity Approved by the audit	1.90	0.00	0.00	0									+	
6 A	kem Laboratories Limited	AABCA9521E	Limited Cachet Pharmaceuticals Private Limited	AAACC9312J	Subsidiary	Any other transaction	Reimbursement of expenses to counterparty	50.00	committee of the entity Approved by the audit committee of the entity	0.14	0.00	0.00	þ									1	
7 A	kem Laboratories Limited	AABCA9521E	Indchemie Health Specialities	AAACI1070P	Subsidiary	Purchase of goods or	counterparty	1500.00	Approved by the audit	371.58	170.52	177.18	3									1	
8 A	Ikem Laboratories Limited	AABCA9521E	Private Limited Indchemie Health Specialities	AAACI1070P	Subsidiary	services Sale of goods or		100.00	committee of the entity Approved by the audit	0.00	0.00	0.00	0								1	+	
9 A	Ikem Laboratories Limited	AABCA9521E	Private Limited Indchemie Health Specialities	AAACI1070P	Subsidiary	services Any other transaction	Services received	900.00	committee of the entity Approved by the audit	156.99	170.52	177.18	3									+	
10 A	Ikem Laboratories Limited	AABCA9521E	Private Limited Indchemie Health Specialities	AAACI1070P	Subsidiary	Any other transaction	Services rendered	5.0	committee of the entity Approved by the audit	0.05	5 0.00	0.00	2		1							+	
11 A	Ikem Laboratories Limited	AABCA9521E	Private Limited Indchemie Health Specialities	AAACI1070P	Subsidiary	Any other transaction	Rent Income	30.0	committee of the entity Approved by the audit	6.34	4 0.00	0.00	2		+	1						+	
12 A	Ikem Laboratories Limited	AABCA9521E	Private Limited Enzene Biosciences Limited	AABCE6662L	Subsidiary	Purchase of goods or		521.3	committee of the entity Approved by the audit	143.85	5 284.42	54.73	3		+							+	
13 A	Ikem Laboratories Limited	AABCA9521E	Enzene Biosciences Limited	AABCE6662L	Subsidiary	services Any other transaction	Royalty income	39.3	committee of the entity Approved by the audit	7.08	3 284.42	54.73	3		+							+	
14 A	Ikem Laboratories Limited	AABCA9521E	Galpha Laboratories Limited	AABCG2175Q	Affiliate	Purchase of goods or		1000.0	committee of the entity Approved by the audit	177.62	2 88.88	70.67	7									+	
15 A	Ikem Laboratories Limited	AABCA9521E	Galpha Laboratories Limited	AABCG2175Q	Affiliate	services Any other transaction	Rent Income	50.0	committee of the entity Approved by the audit	1.92	2 88.88	70.67	7		+							+	
16 A	lk∈m Laboratories Limited	AABCA9521E	Galpha Laboratories Limited	AABCG2175Q	Affiliate	Sale of goods or		50.0	committee of the entity Approved by the audit	9.05	5 88.88	70.67	7									+-	
	Jkem Laboratories Limited		Ms. Divya Singh	DCBPS1593G	Relatives of Key Managerial Personnel	services Any other transaction	Consultancy fees		committee of the entity As per approval of Board of Directors or Shareholders of the entity as necessary	1.50	0.00	0.00	D									-	
18 A	lkem Laboratories Limited	AABCA9521E	Mr. Rajesh Dubey	AAHPD0258Q		Any other transaction	Loan given - received back		Not applicable	0.80	0 3.00	2.20	0									-	
19 A	Ikem Laboratories Limited	AABCA9521E	Mr. Rajesh Dubey	AAHPD0258Q	Key Managerial Personnel	Interest income			Not applicable	0.06	6 3.0	2.20	0										
20 /	Ikem Laboratories Limited	AABCA9521E	Mrs. Madhurima Singh	ANRPS6925N	Key Managerial Personnel	Any other transaction	Rent expenses	3.0	D Approved by the audit committee of the entity	0.99	9 0.0	0.00	0										
21 /	Nkem Laboratories Limited	AABCA9521E	Mr. Sarvesh Singh	ANNPS1327G	Key Managerial Personnel	Any other transaction	Rent expenses	2.0	D Approved by the audit committee of the entity	0.52	2 0.0	0.00	o										
22 /	Nkem Laboratories Limited	AABCA9521E	Ms. Divya Singh	DCBPS1593G	Relatives of Key Managerial Personnel	Any other transaction	Rent expenses	2.0	D Approved by the audit committee of the entity	0.57	7 0.0	0.00	0										
23 /	Nk∋m Laboratories Limited	AABCA9521E	Mr. Basudeo Narain Singh	AKZPS2803A	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	107.4	9 0.0	0.00	0										
24 /	Nkem Laboratories Limited	AABCA9521E	Late Mr. Balmiki Prasad Singh	AMMPS2252G	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	25.4	9 0.0	0.01	0										
25 /	Alleem Laboratories Limited	AABCA9521E	Mr. Mritunjay Kumar Singh	AKZPS2801C	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	51.2	2 0.0	0.0	0										
26	Alkem Laboratories Limited	AABCA9521E	Mr. Sandeep Singh	AKZPS2801C	Key Manageria Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	51.5	9 0.0	0.0	0										
27	Alkem Laboratories Limited	AABCA9521E	Mr. Sarvesh Singh	ANNPS1327G	Key Manageria Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	21.1	7 0.0	0 0.0	10										
28	Alkem Laboratories Limited	AABCA9521E	Mrs. Madhurima Singh	ANRPS6925N	Key Manageria Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	44.5	i4 0.0	0 0.0	00										
29	Alkem Laboratories Limited	AABCA9521E	Mr. A.K.Purwar	ADXPP9783F	Key Manageria Personnel	Sitting fees and commission			As per approval of Board of Directors or Shareholders of th entity as necessary	e 1.4	0 0.0	0 0.0											
	Alkem Laboratories Limited	AABCA9521E		AADPS0034K	Personnel	Sitting fees and commission			As per approval of Board of Directors or Shareholders of th entity as necessary														
31	Alkem Laboratories Limited	AABCA9521E	Ms. Sangeeta Singh	ANTPS7428L	Key Manageria Personnel	I Sitting fees and commission			As per approval of Board of Directors or Shareholders of th entity as necessary	e 1.3	95 O.C	0 0.0	00										

## Rs.In million Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

p         entering into the transaction as approved by heauting committies         party transaction as approved committies         party transaction committies         party transactin committies         party transaction committie											such transaction was undertaken.											
Image: Probability         Probability <th>Sr Details of the party (listed en ND. entering into the trans</th> <th colspan="2">St Details of the party (listed entity /subsidiary) Details of No. entering into the transaction</th> <th>counterparty</th> <th></th> <th></th> <th>party transaction</th> <th>related party transaction as approved</th> <th>ty committee I</th> <th>transaction during the</th> <th>due to eith a resul</th> <th>er party as It of the</th> <th></th> <th>er-corporate depo</th> <th></th> <th></th> <th>Details of the</th> <th>loans, inter-c</th> <th>orporate de</th> <th>posits, advanc</th> <th>es or investments</th> <th>Notes</th>	Sr Details of the party (listed en ND. entering into the trans	St Details of the party (listed entity /subsidiary) Details of No. entering into the transaction		counterparty			party transaction	related party transaction as approved	ty committee I	transaction during the	due to eith a resul	er party as It of the		er-corporate depo			Details of the	loans, inter-c	orporate de	posits, advanc	es or investments	Notes
n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n         n		D DANI	himme	DAM	Polationship (								Notice of	Datails of all	I Cort	Torus	Notige (land	Internet	Tenura	Securedi	Durpage for which #	1
					the counterparty with the listed entity or its subsidiary						balance	balance .	indebtedness (loan/ issuance of debt/ any other etc.)		Cost	i en xure	advance/ intercorporate		renure		funds will be utilised by the ultimate recipient of	
Image:         Image:        Image:        Image: </td <td>32 Alkern Laboratories Limited</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Directors or Shareholders of the entity as necessary</td> <td></td>	32 Alkern Laboratories Limited								Directors or Shareholders of the entity as necessary													
Name         Name </td <td>33 Alkem Laboratories Limited</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Directors or Shareholders of the</td> <td></td> <td></td> <td>0.00</td> <td></td>	33 Alkem Laboratories Limited								Directors or Shareholders of the			0.00										
Image: state	34 Alkem Laboratories Limited	AABCA9521E	Mr. Narendra Kumar Aneja	AADPA5229J					Directors or Shareholders of the		0.00	0.00										
Image: Section of the secti	35 Alkem Laboratories Limited	AABCA9521E	Mr. Rajesh Dubey	AAHPD0258Q		Remuneration			Directors/ Shareholders/ NRC	15.67	0.00	0.00										
Image: Sector	36 Alkem Laboratories Limited	AABCA9521E	Mr. Manish Narang	AAHPN6263D		Remuneration			Directors/ Shareholders/ NRC	9.20	0.00	0.00										
Image: Problem	37 Alkern Laboratories Limited	AABCA9521E	Mr. Satish Kumar Singh	ANXPS0460J	Managerial	Remuneration			Directors/ Shareholders/ NRC	33.78	3 0.00	0.00										
Normal walk	38 Alkern Laboratories Limited	AABCA9521E	Mr. Sarandhar Singh	AYJPS5262R	Managerial	Remuneration			Directors/ Shareholders/ NRC	20.58	3 0.00	0.00										
No         No        No        No         No <td>39 Alkem Laboratories Limited</td> <td>AABCA9521E</td> <td>Mr. Srinivas Singh</td> <td>AYJPS5262R</td> <td>Managerial</td> <td>Remuneration</td> <td></td> <td></td> <td>Directors/ Shareholders/ NRC</td> <td>20.95</td> <td>5 0.00</td> <td>0.00</td> <td></td>	39 Alkem Laboratories Limited	AABCA9521E	Mr. Srinivas Singh	AYJPS5262R	Managerial	Remuneration			Directors/ Shareholders/ NRC	20.95	5 0.00	0.00										
And Loburter Line         Add 200         And 200	40 Alkem Laboratories Limited	AABCA9521E	Alkem Laboratories Corporation	NA	Subsidiary			200.0		39.83	3 152.22	63.54										-
Image: Constraint of the ima	41 Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories, LLC	NA		Sale of goods or		25100.0		6400.90	9257.88	9843.55										
10 Algebra       10 Algebra </td <td>42 Alkem Laboratories Limited</td> <td>AABCA9521E</td> <td>Ascend Laboratories SpA</td> <td>NA</td> <td></td> <td>Sale of goods or</td> <td></td> <td>3000.0</td> <td>0 Approved by the audit</td> <td>546.76</td> <td>6 1610.05</td> <td>2174.15</td> <td>5</td> <td></td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	42 Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories SpA	NA		Sale of goods or		3000.0	0 Approved by the audit	546.76	6 1610.05	2174.15	5		1							
144 Marcination       145 Marcination       Marcinat	43 Alkem Laboratories Limited	AABCA9521E	The Pharmanetwork, LLP	NA	Subsidiary	Sale of goods or		620.0	0 Approved by the audit	208.23	3 124.80	326.67	,		1							-
13 Machand       46 Machand </td <td>44 Alkem Laboratories Limited</td> <td>AABCA9521E</td> <td>Pharmacor Pty Limited</td> <td>NA</td> <td>Subsidiary</td> <td>Sale of goods or</td> <td></td> <td>2000.0</td> <td>0 Approved by the audit</td> <td>772.20</td> <td>0 691.83</td> <td>448.23</td> <td>5</td> <td></td> <td>+</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	44 Alkem Laboratories Limited	AABCA9521E	Pharmacor Pty Limited	NA	Subsidiary	Sale of goods or		2000.0	0 Approved by the audit	772.20	0 691.83	448.23	5		+							
44       Machandrame       Machandram       Machandrame <th< td=""><td>45 Alkem Laboratories Limited</td><td>AABCA9521E</td><td>Ascend GmbH</td><td>NA</td><td>Subsidiary</td><td>Sale of goods or</td><td></td><td>200.0</td><td>0 Approved by the audit</td><td>78.37</td><td>7 82.78</td><td>3 103.36</td><td>ő</td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td><math>\vdash</math></td></th<>	45 Alkem Laboratories Limited	AABCA9521E	Ascend GmbH	NA	Subsidiary	Sale of goods or		200.0	0 Approved by the audit	78.37	7 82.78	3 103.36	ő		1							$\vdash$
Phone       Phone <th< td=""><td>46 Alkem Laboratories Limited</td><td>AABCA9521E</td><td>Ascend Laboratories SAS</td><td>NA</td><td>Subsidiary</td><td>Sale of goods or</td><td></td><td>100.0</td><td>0 Approved by the audit</td><td>11.50</td><td>9.03</td><td>3 16.32</td><td>2</td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td><math>\square</math></td></th<>	46 Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories SAS	NA	Subsidiary	Sale of goods or		100.0	0 Approved by the audit	11.50	9.03	3 16.32	2		-							$\square$
44       44       44       44       44       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45 <t< td=""><td>47 Alkem Laboratories Limited</td><td>AABCA9521E</td><td>Pharmacor Limited</td><td>NA</td><td>Subsidiary</td><td>Sale of goods or</td><td></td><td>200.0</td><td>0 Approved by the audit</td><td>28.66</td><td>6 83.02</td><td>2 119.41</td><td></td><td></td><td>-</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td><math>\square</math></td></t<>	47 Alkem Laboratories Limited	AABCA9521E	Pharmacor Limited	NA	Subsidiary	Sale of goods or		200.0	0 Approved by the audit	28.66	6 83.02	2 119.41			-	1						$\square$
46       Applicability       Applicability      <	48 Alkem Laboratories Limited	AABCA9521E		NA	Subsidiary	Sale of goods or		500.0	0 Approved by the audit	112.24	4 311.52	316.15	5			1						+
0         Name         Na	49 Alkem Laboratories Limited	AABCA9521E		NA	Subsidiary	Sale of goods or		100.0	0 Approved by the audit	21.56	6 30.07	7 33.93	3		-							+
19         Name         Add 2000 med 2 Cline Phone Main         Add 2 Cline Phone Mai	50 Alkem Laboratories Limited	AABCA9521E	S&B Pharma , LLC	NA		Sale of goods or		100.0	0 Approved by the audit	27.98	8 61.33	3 78.85	5		-	-						+
R2       Amel Laboratorise Lined       Advances       Mainabase (main and presenting laboration service)       Raise (m	51 Alkem Laboratories Limited	AABCA9521E	Connect 2 Clinic Private Limited	AAICC7144C			Services received	200.0	0 Approved by the audit	57.8	7 21.48	8 10.75	5		-							+
S3         Alex Laboratories Limited         Alex CAS221         Alex Laboratories Corporation         NA         S0         No         NA         NA        NA        NA        NA         NA        NA	52 Alkem Laboratories Limited	AABCA9521E	ThePharmaNetwork, LLC	NA	Subsidiary	Any other transaction	Services received	2000.0	0 Approved by the audit	423.0	5 9257.88	9843.55	5			+						+
54       Alem Laboratories Limited       AB2A921E       Nem Laboratories Corporation       NA       Subsidiary       Any other transaction       Lang year-received back       Best and or approval / Board of performations       Best and or approval / Board of permitions       Be	53 Alkem Laboratories Limited	AABCA9521E	Alkem Laboratories Corporation	NA	Subsidiary		/		As per approval of Board of Directors or Shareholders of the		5 0.00	0.00	2				Investment	NA	NA	NA		$\top$
SA       AABCARS2E       Alker Foundation       AAACARSSE       Subsidiary       Any other transaction       Donations given       9800 Apprived by the audit committee of the entity.       259.32       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00	54 Alkem Laboratories Limited	AABCA9521E	Alkem Laboratories Corporation	NA	Subsidiary	Any other transaction			As per approval of Board of Directors or Shareholders of the		6 89.20	0.00	0									T
56       Alsen Laboratories Limited       A8A S0A9S1E       Asec And Laboratories SpA       NA       Subsidiary       Any offer transaction       Subsidiary       Not applicable       19       1610.0       217.4 i       Columnation       Columnation       Columnation       Not applicable       19       1610.0       217.4 i       Columnation       Columnation       Columnation       Columnation       Columnation       Not applicable       0.2       115.4       120.6       Columnation       Columnation <thcolumnation< th="">       Columnation</thcolumnation<>	55 Alkem Laboratories Limited	AABCA9521E	Alkem Foundation	AAICA6895L	Subsidiary	Any other transaction	Donations given	560.0	0 Approved by the audit	259.3	2 0.00	0.00	D									
All       A	56 Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories SpA	NA	Subsidiary	Any other transaction	Guarantee commission	n		1.9	5 1610.05	5 2174.15	5									1
Algorithm         Algorithm <t< td=""><td>57 Alkem Laboratories Limited</td><td>AABCA9521E</td><td>Pharmacor Pty Limited</td><td>NA</td><td>Subsidiary</td><td>Any other transaction</td><td>Guarantee commission</td><td>n</td><td>Not applicable</td><td>0.2</td><td>0 115.4</td><td>5 120.64</td><td>4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td></t<>	57 Alkem Laboratories Limited	AABCA9521E	Pharmacor Pty Limited	NA	Subsidiary	Any other transaction	Guarantee commission	n	Not applicable	0.2	0 115.4	5 120.64	4									1
59       Alkem Laboratories Limited       Assch43221E       Ascend Laboratories, LLC       NA       Step down subsidiary       Ary other transaction       Royally income       200.00       Approved by the audit committee of the entity       46.51       9257.88       9843.55       Image: Committee of the entity       Image:	58 Alkem Laboratories Limited	AABCA9521E	Pharma Network SpA	NA		Any other transaction	Guarantee commission	n	Not applicable	0.2	3 0.30	0 0.70	D		-							+
60       Alker Laboratories Limited       AseCA9521E       Asecn Laboratories, LLC       NA       Step down subsidiary       Any other transaction subsidiary       Nave transaction subsidia	59 Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories, LLC	NA	Step down	Any other transaction	Royalty income	200.0	0 Approved by the audit	46.5	1 9257.8	8 9843.55	5									1
61       AkeCA9521E       Pharmacor Pty Limited       NA       Subsidiary       Ary other transaction expenses to counterparty       400.00 counterparty       Approved by the audit committee of the entity       96.34       115.45       120.64       Image: Conterparty       I	60 Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories, LLC	NA	Step down	Any other transaction	expenses to	100.0	0 Approved by the audit	12.7	9 53.8	9 273.35	5			1						T
62       Alkem Laboratories Limited       AABCA9521E       Ascend GmbH       NA       Subsidiary       Any other transaction       Reimbursement of expenses to counterparty       75.00       Approved by the audit committee of the entity       555       12.52       17.24       Image: Committee of the entity       Image: Committee of the entity       Image: Committee of the entity       555       12.52       17.24       Image: Committee of the entity       150.00       Approved by the audit committee of the entity       2.09       9.93       11.03       Image: Committee of the entity       Image: Committee of the entity       Image: Committee of the entity       150.00       Approved by the audit committee of the entity       2.09       9.93       11.03       Image: Committee of the entity       Image: Committee of the entity       Image: Committee of the entity       100.00       Approved by the audit committee of the entity       8.94       25.85       36.95       Image: Committee of the entity       Image: Committee of the	61 Alkem Laboratories Limited	AABCA9521E	Pharmacor Pty Limited	NA	Subsidiary	Any other transaction	Reimbursement of expenses to	400.0		96.3	4 115.4	5 120.64	4									
83       Akem Laboratories Limited       AABCA9521E       Ascend Laboratories (UK)       NA       Subsidiary       Ary other transaction       Reimbursement of expenses to counterparty       150,00       Approved by the audit counterparty       2.09       9.93       11.03       Image: Counterparty       Image: Co	62 Alkem Laboratories Limited	AABCA9521E	Ascend GmbH	NA	Subsidiary	Any other transaction	Reimbursement of expenses to	75.0		5.5	5 12.5	2 17.24	4									
CV subsidiary expenses to committee of the entity	63 Alkem Laboratories Limited	AABCA9521E		NA	Subsidiary	Any other transaction	Reimbursement of expenses to	150.0		2.0	9.9	3 11.0	3									
	64 Alkern Laboratories Limited	AABCA9521E	Ascend Laboratories S.A. DE. CV	NA		Any other transaction	expenses to	100.0		8.9	4 25.8	5 36.9	5									

Rs.in million
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits,
advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when
such transaction was undertaken.

										such transaction was undertaken. es are In case any financial indebtedness is incurred to make Details of the loans, inter-corporate deposits, advances or investments No												
Sr No.	Eetails of the party (listed entity /subsidiary) Details of the counterparty entering into the transaction					Type of related party transaction party transaction related yarty con transaction as approved	Remarks on approval by audit committee	i by audit Value of in case mo transaction due to either during the a result reporting transac			In case any financ or give loans, inte	al indebtedness is er-corporate depo- investments	sits, adv	i to make ances or	Details of the loans, inter-corporate deposits, advances or investments							
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee		period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised b the utimate recipient o funds (endusage)	y
65 A	Ikem Laboratories Limited	AABCA9521E	S&B Pharma , LLC	NA	Step down subsidiary	Any other transaction	Reimbursement of expenses to counterparty	50.00	Approved by the audit committee of the entity	0.24	61.33	78.85	5									
66 A	Ikem Laboratories Limited	AABCA9521E	Ascend Laboratories SpA	NA	Subsidiary	Any other transaction	Reimbursement of expenses from counterparty	50.00	Approved by the audit committee of the entity	6.60	1610.05	2174.15	5									
67 A	Ikem Laboratories Limited	AABCA9521E	Pharma Network SpA	NA	Step down subsidiary	Any other transaction	Reimbursement of expenses from counterparty	50.0	D Approved by the audit committee of the entity	0.10	0.30	0.70	D									
68 A	Ikem Laboratories Limited	AABCA9521E	Connect 2 Clinic Private Limited	AAICC7144C	Subsidiary	Any other transaction	Reimbursement of expenses from counterparty	50.0	D Approved by the audit committee of the entity	1.59	0.00	0.00	D									
69 A	lkem Laboratories Limited	AABCA9521E	Alkem Laboratories Corporation	NA	Subsidiary	Interest income			As per approval of Board of Directors or Shareholders of the entity as necessary	0.79	89.20	0.00	D									
70 4	Jkem Laboratories Limited	AABCA9521E	Alkem Laboratories Korea Inc.	NA	Subsidiary	Interest income			As per approval of Board of Directors or Shareholders of the entity as necessary	0.05	5 1.64	1.81	1									
71	lk∈m Laboratories Limited	AABCA9521E	Ascend Laboratories SDN BHD.	NA	Subsidiary	Interest income			As per approval of Board of Directors or Shareholders of the entity as necessary	0.04	1.19	1.32	2									
72	Ikem Laboratories Limited	AABCA9521E	Ascend Laboratories, LLC	NA	Step down subsidiary	Any other transaction	Services rendered	500.0	0 Approved by the audit committee of the entity	155.82	9257.88	9843.55	5									
73	Ikem Laboratories Limited	AABCA9521E	Ascend Laboratories SpA	NA	Subsidiary	Any other transaction	Services rendered	100.0	0 Approved by the audit committee of the entity	23.02	2 1610.05	2174.15	5									
74	Alkem Laboratories Limited	AABCA9521E	Pharmacor Pty Limited	NA	Subsidiary	Any other transaction	Services rendered	100.0	0 Approved by the audit committee of the entity	1.26	691.83	448.23	3									
	ndchemie Health Specialities Private Limited	AAACI1070P	Galpha Laboratories Limited	AABCG2175Q	Affiliate	Any other transaction	Services rendered	50.0	0 Approved by the audit committee of the entity	0.67	7 1.27	0.00	0									1
76	ndchemie Health Specialities Private Limited	AAACI1070P	Cachet Pharmaceuticals Private Limited	AAACC9312J	Fellow Subsidiary Company	Sale of goods or services		100.0	0 Approved by the audit committee of the entity	32.12	2 5.20	8.98	8									-
	ndchemie Health Specialities Pri∿ate Limited	AAACI1070P	Mr. Mritunjay Kumar Singh	AKZPS2801C		Any other transaction	Rent expenses		Not applicable	0.12	2 0.00	0.00	0									
	Cachet Pharmaceuticals Private Limited	AAACC9312J	Galpha Laboratories Limited	AABCG2175Q	Affiliate	Purchase of goods or services		150.0	0 Approved by the audit committee of the entity	3.51	1 5.25	5 1.85	5									
79	Cachet Pharmaceuticals Private irrited	AAACC9312J	Mr. Satish Kumar Singh	ANXPS0460J	Key Managerial Personnel	Interest income			Not applicable	2.52	2 86.52	2 88.79	9									
80	Enzene Biosciences Limited	AABCE6662L	Mr Himanshu Gadgil	AZGPG4321H	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	7.19	9 0.00	0.00	0									
81	Enzene Biosciences Limited	AABCE6662L	Mr Viral Shah	BCZPS6891M	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	6.2	1 0.00	0.00	0									1
82	Enzene Biosciences Limited	AABCE6662L	Ms Renu Sharma	BGEPS6345B	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC	0.40	0 0.00	0.00	10									+
									of the entity as necessary													_
83	Enzene Biosciences Limited	AABCE6662L	Ms Shilpa Gadgil	AZAPG2911M	Relatives of Key Managerial Personnel	Remuneration	· .		As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	3.8	3 0.0	0.01	0									
84	Pharmacor Pty Limited		Mr Ashish Mallela		Key Managerial Personnel	Remuneration			Not applicable	11.7	9 0.0	0 0.0	00									1
85	Pharmacor Pty Limited		Mr Richard Mlynarick		Key Managerial Personnel	Remuneration			Not applicable	10.1	8 0.0	0 0.0	00									
86	Ascend Laboratories, SpA		Mr Rahul Bhat		Key Managerial Personnel	Remuneration			Not applicable	12.1:	2 0.0	0 0.0	00									
87	Ascend Laboratories, SpA		Mr Rahul Bhat		Key Managerial Personnel	Interest income			Not applicable	0.0	2 7.8	4 6.4	17									
	Ascend Laboratories, SpA		Mr Rahul Bhat		Personnel	Any other transaction	Loan taken repaid		Not applicable	1.2												
	Ascend GmbH		Mr Vikas Singh		Personnel	Remuneration			Not applicable	8.0												
	Ascend GmbH		Mr Vikas Singh	2	Personnel	Any other transaction	Loan taken repaid		Not applicable	0.6												
	The PharmaNetwork LLP		Mr Viralkumar Girishkumar Parikh		Personnel	Remuneration			Not applicable	10.3												
	Pharmacor Limited		Mr Nikhilesh Shrivastava		Personnel	Remuneration			Not applicable	7.9												
93	Ascend Laboratories (UK) Ltd		Ascend GmbH		Fellow Subsidiary Company	Interest income			Not applicable	0.5	68 43.2	41.5	59									

Rs.In million Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

																such transaction v	vas undertak	en.				
Sr Details of the party (listed entity /subsidian o. entering into the transaction			Details of the	Type of related party transaction	Details of other relation		ty committee	transaction during the reporting	due to eith a resu	nonies are her party as lt of the action	In case any financi or give loans, inte											
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee		period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient o funds (endusage)	y
14	Ascend Laboratories (UK) Ltd		Ascend Laboratories SAS		Fellow Subsidiary Company	Interest income			Not applicable	0.10	4.15	4.57	7									
5	The Pharma Network, LLC		S&B Pharma , LLC		Subsidiary	Purchase of goods or services			Not applicable	658.77	151.62	291.10										T
6	The ⊃harma Network, LLC		S&B Pharma , LLC		Subsidiary	Any other transaction	Reimbursement of expenses to counterparty		Not applicable	6.09	269.95	389.05	5									T
	The Pharma Network, LLC		S&B Pharma , LLC		Subsidiary	Interest income			Not applicable	8.23												+
	The Pharma Network, LLC Alkem Laboratories Limited	AABCA9521E	S&B Pharma , LLC Enzene Biosciences Limited	AABCE6662L	Subsidiary Subsidiary	Any other transaction Any other transaction	Loan given Licensing fees paid	700.00	Not applicable Approved by the audit committee of the entity	137.18 139.74					-							+
0	Alkem Laboratories Limited	AABCA9521E	Mr. Rajesh Dubey	AAHPD0258Q	Key Managerial Personnel	Any other transaction	Loan given		Not applicable	3.00	3.00	2.20	D									T
1	Alkem Laboratories Limited	AABCA9521E	S&B Pharma , LLC	NA	Step down subsidiary	Any other transaction	Royalty income	100.00	Approved by the audit committee of the entity	5.67	61.33	78.85	5									t
12	Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories SAS	NA	Subsidiary	Any other transaction	Reimbursement of expenses to	50.00	Approved by the audit committee of the entity	1.09	2.14	4 0.00	D									t
13	Alkem Laboratories Limited	AABCA9521E	Ascend Laboratories, LLC	NA	Step down subsidiary	Any other transaction	counterparty Reimbursement of expenses from	200.00	Approved by the audit committee of the entity	2.44	9257.88	9843.55	5									t
4	Alkem Laboratories Limited	AABCA9521E	Pharmacor Pty Limited	NA	Subsidiary	Any other transaction	counterparty Reimbursement of expenses from	80.00	Approved by the audit committee of the entity	27.02	691.8	3 448.23	3									T
15	Alkem Laboratories Limited	AABCA9521E	Indchemie Health Specialities Private Limited	AAACI1070P	Subsidiary	Dividend received	counterparty		As per approval of Board of Directors or Shareholders of the entity as necessary	35.70	0.00	0.00	D									t
	Indchemie Health Specialities	AAACI1070P	Galpha Laboratories Limited	AABCG2175Q	Affiliate	Purchase of goods or		50.00	Approved by the audit committee of the entity	2.03	3 0.00	0.29	9		1							T
	Private Limited Enzene Biosciences Limited	AABCE6662L	Ms Aishwarya Bapat	BDPPB3691B	Key Managerial Personnel	services Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	0.05	5 0.0	0.00	D									T
08	The Pharma Network, LLC		Mr Amit Ghare		Key Managerial Personnel	Remuneration			Not applicable	41.94	4 0.0	0.0	0									+
09	The Pharma Network, LLC		Mr James Gregory Giuliano		Key Managerial Personnel	Remuneration			Not applicable	15.89	0.0	0.0	0		-							+
10	The Pharma Network, LLC		Mr William Moran		Key Managerial Personnel	Remuneration			Not applicable	8.28	3 0.0	0.0	0									+
11	The Pharma Network, LLC		Mr John Dillaway		Key Managerial Personnel	Remuneration		-	Not applicable	23.99	9 0.0	0.0	0		+							+
12	The Pharma Network, LLC		Mr Hindy Schiff		Key Managerial Personnel	Remuneration			Not applicable	13.50	0.0	0 0.0	0									+
13	The Pharma Network, LLC		Mr Schuyler Van Winkle		Key Managerial Personnel	Remuneration		1.	Not applicable	20.90	0.0	0 0.0	0		+							+
14	The Pharma Network, LLC		Mr Sandeep Singh		Key Managerial Personnel	Remuneration		1	Not applicable	32.13	3 0.0	0_0.0	0		+							+
15	Cachet Pharmaceuticals Private Limited	AAACC9312J	Mr. Arunkumar Deshmukh	ABSPD0968P	Key Managerial Personnel	Sitting fees			As per approval of Board of Directors or Shareholders of the	0.05	5 0.0	0 0.0	0									+
16	Cachet Pharmaceuticals Private Limited	AAACC9312J	Dr. Anuja Sinha	AKLPS5093C	Key Managerial Personnel	Sitting fees			entity as necessary As per approval of Board of Directors or Shareholders of th	e 0.03	3 0.0	0 0.0	0		+							+
17	Indchemie Health Specialities Prvate Limited	AAACI1070P	Mr Akhouri Maheshwari Prasad	AFEPP2852G	Key Managerial Personnel	Sitting fees			entity as necessary As per approval of Board of Directors or Shareholders of th	0.14	4 0.0	0 0.0	0					1	1			+
8	Indchemie Health Specialities Private Limited	AAACI1070P	Mr Gautam Gulabchand Parekh	AABPP6647F	Key Managerial Personnel	Sitting fees			entity as necessary As per approval of Board of Directors or Shareholders of th	0.16	6 0.0	0 0.0	0									+
19	Enzene Biosciences Limited	AABCE6662L	Mr. R.L.Shenoy	AADPS0034K	Key Managerial Personnel	Sitting fees			entity as necessary As per approval of Board of Directors or Shareholders of th	e. 0.04	4 0.0	0 0.0	0					1	1			+
20	Enzene Biosciences Limited	AABCE6662L	Ms. Sangeeta Singh	ANTPS7428L	Key Managerial Personnel	Sitting fees			entity as necessary As per approval of Board of Directors or Shareholders of th entity as necessary	e 0.0	6 0.0	0 0.0	0									+
21	Enzene Biosciences Limited	AABCE6662L	Ms. Sudha Ravi	ATCPS4815L	Key Managerial Personnel	Sitting fees			As per approval of Board of Directors or Shareholders of th entity as necessary	0.1	0 0.0	0 0.0	0									T
22	Ascend Laboratories, SpA		Mr Rahul Bhat		Key Managerial Personnel	Any other transaction	Reimbursement of expenses to counterparty		Not applicable	1.4	5 0.0	0 0.0	0									T
23	Ascend Laboratories, SpA	1	Mr Ashish Mallela		Key Managerial Personnel of fellow	Remuneration	counterparty		Not applicable	3.3	4 0.0	0 0.0	10									+
					Subsidiary																	

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Rs.in million

												such transaction was undertaken.											
Sr Nio.	Cetails of the party (listed en entering into the tran	saction	Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit	Remarks on approval by audit committee	Value of transaction during the reporting period	due to either party as a result of the transaction		In case any financia or give loans, inte	r-corporate depo investments	sits, adv	ances or							
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			committee			Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
124	Pharmacor Limited		Mr Nikhilesh Shrivastava		Key Managerial Personnel	Any other transaction	Reimbursement of expenses to counterparty		Not applicable	0.37	0.10	0.47	,										
125	Pharmacor Limited		Mr Nikhilesh Shrivastava		Key Managerial Personnel	Any other transaction	Loan given		Not applicable	2.74	0.00	2.08	8										
*26	Pharmacor Limited		Mr Nikhilesh Shrivastava		Key Managerial Personnel	Any other transaction	Loan taken repaid		Not applicable	1.03	0.00	2.08	3										
127	Ascend Laboratories SAS		Mr Pankaj Sawant		Key Managerial Personnel	Remuneration			Not applicable	3.12	2 0.00	0.00	D										
128	Ascend Laboratories SAS		Mr Pankaj Sawant		Key Managerial Personnel	Any other transaction	Loan given		Not applicable	1.81	0.00	1.81											
129	The Pharma Network, LLC		Mr Amit Ghare		Personnel	Any other transaction	Loan taken repaid		Not applicable	7.36	5 14.50	6.70	כ										
130	Alkem Laboratories Limited		Mr. Sujjain Talwar		Key Managerial Personnel	Sitting fees and commission			As per approval of Board of Directors or Shareholders of the entity as necessary	0.40	0.00	0.00	ס										
131	Alkem Laboratories Limited	AABCA9521E	Mr. Srinivas Singh	AYJPS5262R	Key Managerial Personnel	Remuneration			As per approval of Board of Directors/ Shareholders/ NRC of the entity as necessary	5.68	8 0.00	0.00	D										
132	S&B Pharma , LLC		Mr. Les Ordway		Key Managerial Personnel	Remuneration			Not applicable	7.36	5 0.00	0.00											
133	Alkem Laboratories Limited	AABCA9521E	Mr. Sarvesh Singh	ANNPS1327G	Key Managerial Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.30	0.00	0.00	ס										
134	Alkem Laboratories Limited	AABCA9521E	Mr. Sandeep Singh	AKZPS2801C	Key Managerial Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	5.49	9 0.00	0.00	D										
135	Alkem Laboratories Limited	AABCA9521E	Mr. Sarandhar Singh	AYJPS5262R	Relatives of Key Managerial Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.3	0 0.00	0.00	D										
136	Alkem Laboratories Limited	AABCA9521E	Mr. Mritunjay Kumar Singh		Key Managerial Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.0	5 0.00	0.0	D										
	Alkem Laboratories Limited		Mr. Basudeo Narain Singh	AKZPS2803A	Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	1.2													
	Alkem Laboratories Limited		Late Mr. Balmiki Prasad Singh		Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	1.1													
	Alkem Laboratories Limited		Mrs. Madhurima Singh	ANRPS6925N	Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.3													
	Alkem Laboratories Limited	AABCA9521E	Mr. Srinivas Singh	AYJPS5262R	Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.2													
141	Alkem Laboratories Limited	AABCA9521E	Mr. Srinivas Singh	AYJPS5262R	Relatives of Key Managerial Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	3.5	7 0.00	0.0	0										
	Alkem Laboratories Limited	AABCA9521E		AAHPD0258Q	Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.2													
143	Alkem Laboratories Limited	AABCA9521E	Mr. Manish Narang	AAHPN6263D	Key Managerial Personnel	Any other transaction	Reimbursement of expenses from counterparty		Not applicable	0.0	1 0.00	0.0	0										

Nctes

1 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors/Nomination and remuneration Committee of Alkem Laboratories Limited, as applicable, for financial year 2022-23.

2 Amount mentioned as "0.00" denotes value less than ₹ 5,000

2 And/out intended as 0.00 demixed and ease and in 50,000 3 Dividend income from subsidiaries are included in this statement on receipt basis. 4 Transactions of unlisted subsidiaries within the specified thresholds as per SEBI (LODR); Audit committee approval of Alkem Laboratories Limited is not required 5 Transaction between and within Foreign Related Parties have been converted at the average exchange rate for the period, where as the opening and closing balances have been converted at the average exchange rate for the period, where as the opening and closing balances have been converted at the average exchange rate as on the balance sheet date 6 Remuneration paid to employees of the Parent/Subsidiary Company who are appointed as Directors/KMPs on it's subsidiary companies is not disclosed considering that such payment is in accordance with their terms of employment.